Previous 10 | Next 10 |
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is the focus of IBN's latest stock spotlight. The company's shares have moved 2.49% on the day to $17.69. Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people w...
2023-04-04 10:23:00 ET While there's no telling precisely when a new bull market is going to roll around, it will because eventually one always does. That means now's the time to identify shares of businesses that are positioned to soar once sentiment improves. Biotech Catalyst Pharma...
2023-03-31 06:00:00 ET Summary Defense is sometimes the best offense. In the spirit of March Madness and market volatility, it’s time to get defensive as the banking crisis and market uncertainty fuel U.S. recession risks. As stocks fluctuate and the Fed suggests tighter cr...
2023-03-23 08:56:52 ET Popular biotech exchange traded fund SPDR S&P Biotech ETF ( NYSEARCA: XBI ) dropped more than 3% on Wednesday. As a result, the ETF reached a new 8-month low. XBI touched $73.06 a share on Wednesday which marked its lowest level dating back to ...
2023-03-16 11:59:04 ET Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2022 Earnings Conference Call March 16, 2023 08:30 A.M. ET Company Participants Alicia Grande - VP, CFO, and Treasurer Patrick J. McEnany - Chairman, President, and CEO Jeff Del Carmen - Chief Commer...
2023-03-15 16:19:15 ET Catalyst Pharmaceuticals press release ( NASDAQ: CPRX ): Q4 Non-GAAP EPS of $0.31 beats by $0.11 . Revenue of $60.76M (+58.6% Y/Y) beats by $0.12M . Cash and Equivalents were $298 million as of December 31, 2022. Achieved Record 2022 ...
Achieved Record 2022 Total Net Revenues of $214 Million, a 52% YoY Increase Achieved FIRDAPSE® Q4 2022 Net Product Revenues of $61 Million, a 59% YoY Increase Newly Acquired FYCOMPA® Product Expected to be Accretive to EBITDA and EPS in 2023 Reaffirming Forecas...
2023-03-13 06:30:14 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the most important things about finding stocks to buy is having a diversified portfolio. You want to spread your money out in different sectors so you’re not hurt if one part of t...
CORAL GABLES, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare disea...
CORAL GABLES, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients li...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
2024-06-20 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...